ERBB2 and breast carcinoma: An additional incentive for the development of TKIs was the need for therapeutic agents that could pass the blood–brain barrier to treat metastases in the central nervous system, which was increasingly observed in breast cancer patients receiving trastuzumab or other antibody-based treatments targeting HER2.